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1. Introduction 
Ulcerative colitis (UC) is a chronic relapsing disease which runs a rather unpredictable 
clinical course. It usually starts in the 2nd or 3rd decade of life and is associated with an 
increased risk of bowel cancer. Unlike Crohn’s disease, there is a relative paucity of basic 
science research as to the molecular determinants that govern mucosal inflammation and 
subsequent risk of developing colon cancer.  Genetic linkage studies in inflammatory bowel 
disease (IBD) traditionally have focussed on candidate genes and haplotypes in at risk 
individuals but emerging evidence would also suggest the importance of epigenetics. 
Epigenetics is the heritable alteration in gene expression but without alteration in DNA 
sequence. Consequently the human epigenomic project has now been established. In this 
chapter we will discuss emerging epigenetic changes in UC and also newer molecular 
targets that have come to the fore such as telomere dysfunction which, may be used as 
putative biomarkers. 
One of the more common epigenetic alterations includes DNA methylation of the gene 
promoter. Much work has focussed on colon cancer but our group and others have 
identified gene promoter DNA hypermethylation in individuals with UC. Critically these 
epigenetic markings affect key tumour suppressor genes which, are then silenced as a result 
of hypermethylation. This therefore may be a potential pathway by which those with UC 
develop colon cancer and will be explored in further detail in this chapter.  
Similarly telomere dysfunction has been well studied in colon cancer and the ageing 
population but lacking in those with UC. Telomeres are the end of chromosomes and are 
long at birth but get shorter with age. At a critical length the telomere signals the end of a 
cell’s life (apoptosis) but some cells can escape death and instead become neoplastic. There 
is reduction in telomerase enzyme (key regulator in telomere length) in UC as well as 
alteration in key telomere binding proteins (TBP). One such protein is TRF2 which is a 
protein that helps protect telomeres from degrading with age and inflammation thus 
delaying the inevitable changes described earlier. Patients with ulcerative colitis appear to 
have a shortage of this protein and the longer the duration of the disease the less the protein. 
There is also a suggestion that it may also be altered with therapy (immune-modulating) drugs 
used to treat UC. TRF2 may yet provide a candidate protein for a biomarker which we will 
discuss together with the role of other TBPs and its relationship with UC disease activity.  
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This chapter will cover in detail a literature review and summary of current and developing 
work in our lab and others using the headings outlined below: 
2. Epigenetics 
Epigenetic alterations are heritable alterations in gene expression not mediated by alteration 
in DNA sequence i.e. the message is altered but not the gene itself [Jaenisch et al 2003]. Such 
changes include DNA methylation and are among the most common molecular alterations 
in human cancers including colorectal cancer. Other epigenetic changes include histone 
acytelation and protein ubuiquitination. For the purpose of this chapter we will concentrate 
on DNA methylation as it is the most common epigenetic marking and has demonstrable 
changes in UC. 
DNA methylation involves the addition of a methyl group to the carbon-5 position of 
cytosine residues and is the only common covalent modification of human DNA. It occurs 
almost exclusively at cytosines that are followed immediately by guanine (CpG 
dinucleotides). The majority of the genome displays a depletion of CpG dinucleotides and 
those that are present are nearly always methylated. Conversely, small stretches of DNA 
known as CpG islands (usually located within the promoter regions of human genes), whilst 
rich in CpG dinucleotides, are nearly always free of methylation. Methylation of CpGs 
within these islands are associated with transcriptional inactivation of the corresponding 
gene, which, appears to be tissue specific. In colon cancer (CRC) for example, aberrant 
methylation resulting in gene silencing can occur in important tumour suppressor genes 
such as p16INK4a [Merlo et al 1995]. Both genomic DNA hypomethylation as well as gene 
specific (promoter) hypermethylation have been observed in CRC. DNA methylation is vital 
in controlling gene transcription through histone modification. Such conformational 
changes can induce either activation through acetylation for example or repression due to 
methylation of a histone residue – Figure 1. 
Although the methylation profile within the human genome is as yet undetermined, it is 
estimated that 70% of CpG dinucleotides are methylated in mammals. Hypermethylation in 
gene promoter regions are associated with transcriptional silencing which is at least as 
common as inactivation of tumour suppressor genes through DNA mutations [Jones et al 
2002]. Aberrant hypermethylation is thought to be an early event in CRC as it is detectable 
in early precursor lesions e.g. Aberrant Crypt Foci (ACF). Such aberrant changes can occur 
in chronically inflamed tissue which, if involves key tumour suppressor genes may have 
deleterious effects.  
2.1 Age related DNA methylation   
Genomic loss of methylation has been known to occur with ageing. This phenomenon has 
yet to be shown in the normal ageing colon until recently [Arasaradnam 2007]. Most of the 
attention surrounding DNA methylation has been centred on gene specific methylation. In 
the colon, age related methylation accounts for 70% of aberrant gene specific methylation 
events. This process is thought to be a non-stochastic i.e. predictable event and is tissue 
specific. For example, methylation of the ESR1 (tumour suppressor gene) promoter has been 
shown to increase with age in normal human colon and is present also in adenomas thus 
supporting the idea that epigenetic gene silencing is an early event [Issa et al 1994]. Thus it is 
apparent that methylation homeostasis is perturbed with ageing but it is not known if 
ageing is accelerated as a result of if there are consequential effects on other factors such as 
telomere attrition for example (discussed later).  
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Fig. 1. A stretch of genomic DNA in normal and malignant cell. The white pins denote 
unmethylated CpG sites within the promoter region of normal cells which become 
methylated (red pins) during malignant transformation. Conversely, globally the remaining 
CpG dinucleotides are methylated in the normal cell (red pins) and unmethylated in 
malignancy (white pin). The nucleosome (DNA and histones) shown as grey ovals depicts 
the open and closed formation which affects gene transcription either through acetylation 
(green dots) which results in activation or repression due to methylation of certain histone 
residues (pink dots) 
In the aged, as with chronic inflammation (e.g. ulcerative colitis), a critical threshold of 
random accumulation of somatic mutations is thought to be reached leading to the 
development of cancer. However it is more likely due to a combination of effects such as 
cumulative mutational load, epigenetic gene silencing, telomere dysfunction and even 
altered stromal environment [dePinho, 2000]. The perceived key genes regulating this 
process have been studied but with inconsistent results.  
2.2 Influence of dietary factors on DNA methylation 
Epigenetic changes such as DNA methylation are potentially reversible and gene expression 
can be re-established. The active ingredient in Green Tea (EGCG) provides a good example 
of reversal of aberrant methylation with a dietary food component reaffirming the role of 
diet in cancer prevention. The concept of dietary intervention gained further momentum 
following evidence in animal models and epidemiological studies in humans showing that 
folate status can modulate risk of development of colorectal adenoma and cancer. The role 
of folate in UC is discussed further in section 2.3.1. For detailed review on mechanisms of 
diet influencing epigenetics specifically colorectal carcinogenesis please see reference 
[Arasaradnam et al 2008].  
www.intechopen.com
 
Ulcerative Colitis – Epidemiology, Pathogenesis and Complications 
 
120 
2.3 DNA methylation in UC 
Altered DNA methyl transferase (DNMT) activity, histone modification and exogenous 
insults such as diet have been postulated to result in genomic DNA methylation but their 
relative importance in human colonic disease is not well understood (Wilson et al. 2007). 
Apart from folate, little is known if environmental factors or lifestyle factors for example 
smoking patterns, alcohol consumption and diet could influence genomic DNA 
methylation. Furthermore, it would also be important to determine genomic DNA 
methylation in other colonic disease groups – chronic mucosal inflammation, including 
those which predispose to increased risk of CRC e.g. ulcerative colitis. 
2.3.1 DNA global methylation 
UC is a chronic inflammatory condition with an increased risk of developing CRC (Crohn, 
Ginzburg et al. 1984; Ransohoff 1988) especially in those diagnosed at a younger age and 
with greater extent of disease (Ekbom et al. 1990). Genomic instability has been proposed as 
a likely explanation for the observed UC associated CRC risk. Examples of molecular 
determinants used to assess risk in UC include cellular proliferation, genomic DNA 
methylation (Gloria et al. 1996, Arasaradnam et al 2010) and microsatellite instability 
(Tahara, Inoue et al. 2005) amongst others.   
We have shown that using tritium labelled experiments, 3[H] dCTP incorporation into DNA 
was lower in UC patients compared to age and sex matched controls (Arasaradnam et al 
2010). In other words, there was relative genomic hypermethylation in UC subjects 
compared with healthy controls. This finding is in contrast with the only other report a 
decade ago of genomic hypomethylation in UC patients (Gloria et al. 1996). Here the authors 
report genomic hypomethylation in 26 patients with UC compared to 11 controls using the 
methyl acceptance assay. This assay has several limitations (indirect, semi-quantitative and 
prone to false positives due to damaged DNA templates) (Pufulete et al. 2005). They also 
speculate that low levels of S-Adenosyl Methionine (SAM); universal methyl donor in active 
UC coupled by increased cell proliferation may impair DNA methylation status. Conversely 
we have shown that although folate status was lower in UC subjects, it was still within the 
normal reference range. Apart from the different methods employed to quantify genomic 
DNA methylation, the other significant difference was in the proportion of UC patients with 
active disease. The SCAI is a validated scoring system used to identify patients that have 
relapsed after being in remission (Walmsley et al. 1998) . Of note in our study, 5 patients 
(20%) had active disease as opposed to 12 (50%) in the study by Gloria et al - this is likely to 
be an important contributory factor especially as rectal mucosal cells have been shown to 
undergo increased cellular proliferation (Gloria et al. 1996) when disease is active and hence 
incur greater DNA damage. Interestingly, no association was seen with age at diagnosis, 
duration of disease and number of flares with genomic DNA methylation.  
Although red cell folate levels of UC patients in our study were lower than controls, it was 
within normal limits. Previous work (Spiers A et al unpublished) has shown good 
correlation between red cell folate status and mucosal folate levels. Lower levels of folate 
have been attributed to variation in dietary intake, interaction with certain medications 
(sulphapyridines) and increased cell proliferation (Biasco 2005). The normal folate level and 
relative hypermethylation profile in UC patients (mainly quiescent/ mild disease and with 
significantly lower total leucocyte count than controls) may be a consequence of lower rectal 
cell proliferation and increased cell renewal hence altering the genomic DNA methylation 
profile favourably. A further novel finding is that almost 16% of variability in genomic DNA 
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methylation between UC subjects and controls could be explained by BMI alone 
(Arasaradnam 2007). Thus lower BMI is associated with genomic hypermethylation which 
provides support for existing evidence of increasing body fatness being associated with 
increased colon cancer risk (Friedenreich et al. 2006). 
The lower folate status and relative genomic hypermethylation observed in UC subjects 
corroborate a recent report showing a protective effect of low folate status on risk of CRC 
(Van Guelpen et al. 2006). The biological role of folate and DNA methylation in UC is not as 
clear as initially thought and the question of its protective role against CRC, if any, remains 
unclear (Arasaradnam 2010).  
2.3.2 Gene specific methylation in UC 
Epigenetic studies especially in colon carcinogenesis have focussed mainly on gene specific 
methylation. This is not remarkable as gene specific hypermethylation can result in reduced 
gene expression/ silencing with consequent detriment to the colonocyte, particularly, if key 
genes such as tumour suppressor genes (APC, p53, p16INK4a, p14ARF and ESR-1) are involved 
(Issa et al. 1994; Merlo et al. 1995; Esteller 2002). Indeed, most genes hypermethylated in 
tumours originate from the gastrointestinal tract – oesophagus, stomach and colon with 
significantly less reported in other tumour types e.g. ovarian (Esteller et al. 2001). CpG island 
methylation affects several genes including tumour suppressor genes (p16INK4a, p14ARF, APC, 
p53), silencing of DNA mismatch repair genes (hMLH1, O6-MGMT), possible loss of function of 
apoptosis genes (DAPK, APAF-1) and altered carcinogen metabolism (GSTP1) (Esteller 2002).  
Most studies in UC have considered DNA hypermethylation of two genes – Oestrogen 
receptor gene (ESR-1) and Tumour suppressor gene candidate 3 (N-33) – both putative 
tumour suppressor genes. ESR-1 which is located on chromosome 6 has been shown to be 
hypermethylated in the colonic mucosa of those with CRC and to a lesser extent in normal 
individuals (Ahuja et al. 1998). In cell culture, de-methylation of ESR-1 has been shown to 
suppress growth and hence has been proposed to be putative tumour suppressor gene (Issa 
et al. 1994). N-33, also a putative tumour suppressor gene is located on chromosome 8 and 
has been shown in vitro to result in growth suppression of cancer cells. One small study has 
shown hypermethylation of N-33 in both tumour tissue as well as in the normal colon 
(Ahuja et al. 1998). Moreover promoter hypermethylation of both these genes have been 
shown to be age related. 
Little is known about the mucosal inflammatory effect of UC on gene specific methylation. 
Using the COBRA assay, Issa and colleagues found higher methylation of ESR-1 in 12 UC 
subjects with high grade dysplasia or cancer compared with 6 UC patients without 
dysplasia. In that study, methylation levels were comparable for UC patients without 
dysplasia and healthy controls (n = 5). A later study by Tominaga et al (2005), also using the 
COBRA method, reported higher levels of ESR-1 methylation in the neoplastic epithelium of 
UC patients compared with non-neoplastic tissue (25% vs 4% respectively). There were also 
higher levels of methylation in the distal colon compared with the proximal colon but only 
in UC patients with neoplasia. No healthy controls were used. Table 1 summarises the 
studies on gene specific methylation in UC.  
Specifically promoter gene methylation for both ESR-1 and N-33 were significantly higher in 
the macroscopically normal epithelium of UC subjects compared with age and sex matched 
controls (Arasaradnam et al 2010). There was no evidence of dysplasia (confirmed 
histologically) and importantly on subsequent follow up at three years, no cancers were 
identified. A smaller study by Issa et al. showed no difference in ESR-1 methylation between 
controls (n = 5) and UC subjects without dysplasia (n = 6). This lack of a difference may be 
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explained by the relatively small sample size (only 6 UC patients without dysplasia and 5 
controls) compared with the study by Arasaradnam et al. which recruited 68 patients (24 UC 
subjects and 44 age and sex matched controls). Furthermore, the clinical characteristics of 
the UC subjects in the study by Issa et al. were not described in detail. For example, it is not 
known whether the UC subjects without dysplasia had less active, less extensive disease and 
shorter duration of disease compared with those with dysplasia. Importantly no relationship 
between age at diagnosis, disease duration, number of flare-ups, SCCAI score or disease 
extent with promoter methylation of ESR-1 or N-33 was identified (Arasaradnam et al 2010). 
 
Study  
Characteristics 
(Issa, Ahuja et al. 
2001) 
(Fujii, Tominaga 
et al. 2005) 
(Tominaga, Fujii 
et al. 2005) 
(Arasaradnam et 
al. 2010) 
Gene ESR-1, p16, 
hMLH, CSPG2 
ESR-1 ESR-1 ESR-1, MYOD-1, 
N-33 
Sample size 21 30 18 68 
Patient 
Characteristics 
12-HGD/cancer 
6– No Dysplasia 
5 - controls 
13 with cancer 
17 without 
cancer 
8 with cancer 
10 without 
cancer 
24 UC 
44 age & sex 
matched controls 
Assay Method COBRA MSP COBRA COBRA 
Findings Higher 
methylation of 
ESR-1 ,P16 & 
CSPG2 in UC with 
HGD/cancer. 
Controls had 
similar levels to 
UC with dysplasia
Higher ESR-1 
methylation in 
UC with cancer 
compared to 
without. 
 
Higher ESR-1 
methylation in 
UC with cancer 
compared to 
without. 
Methylation 
gradient in colon 
only for those 
with cancer 
Higher ESR-1, N33 
methylation 
compared to 
controls. Lower 
methylation for 
MYOD-1. 
Less smokers 
among UC  
Relationship to 
UC disease 
characteristics 
- No relationship 
between ESR-1 
and 
inflammatory 
activity 
No relationship 
between ESR-1 
and 
inflammatory 
activity 
No relationship 
btw ESR-1, MYOD-
1, N-33 and disease 
activity, duration, 
SCAI score, no. of 
flares or site. 
HGD = High Grade Dysplasia; MSP = Methylation Sensitive PCR (MSP is a sensitive method to detect 
methylation but is not quantitative) 
Table 1. Summary of studies on gene specific methylation in UC.  
The findings of CpG hypermethylation of the putative tumour suppressor genes N-33 and 
ESR-1 in normal tissue suggests that inactivation through methylation of these specific 
putative tumour suppressor genes may not be associated with development of CRC in UC 
patients. The functional role of N-33 in UC remains unknown as yet. 
2.3.3 DNA methylation in UC and colon cancer 
The central pathway (normal epithelium→adenoma→carcinoma) are a result of linear 
accumulation of genetic mutations and/or chromosomal instability in the wnt signalling 
pathway. Mutation of the APC gene and resultant truncated APC products are unable to 
bind to β-catenin resulting in Wnt signalling dysfunction – the latter involved in progression 
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of most sporadic and certain hereditary CRC. It should be noted however that APC 
inactivation is not always the first genetic event and that k-Ras mutations which have been 
observed in normal colonic mucosa as well as in aberrant crypt foci may precede this (Jan 
Willem 2000). CpG methylation is thought to be an early event and may even initiate 
tumourogenesis since it is detected in precursor lesions such as Aberrant Crypt Foci (ACF) and 
adenomatous polyps (Goelz et al. 1985). Consequently Esteller et al (2000) has proposed the 
role of tumour suppressor gene silencing through hypermethylation early in the pathway.  
 
 
APC = Adenomatous Polyposis Coli; CIMP = CpG island methylator phenotype; CIN = Chromosomal 
Instability; DCC = Deleted in Colon cancer; Smad = mothers against decapentaplegic homolog 2,4; 
MMR = Mismatch Repair; TGF = Tumour Growth Factor; BRAF = (v-raf) oncogene homolog B1;  
TSG = Tumour Suppressor Gene; UC = Ulcerative colitis; TRF2 = Telomere Repeat Binding Factor 
Fig. 2. Schematic model for genetic alterations in the development of CRC – modified from 
Fearnhead et al 2001. Incorporates updates of the model to demonstrate possible roles for 
methylation/ telomere dysfunction in the UC - CRC pathway 
Although not well understood, certain genes appear susceptible to silencing through 
hypermethylation. A subset of genes which have particularly high methylation levels have 
been identified in sporadic colon cancers and hence the term CpG island methylator 
phenotype (CIMP) has been coined. Certain subsets of hyperplastic polyps (although the 
precise genetic alterations are unknown) appear to have potential for malignant 
transformation through the hyperplastic polyp→serrated adenoma→adenocarcinoma 
sequence. This has been coined the ‘methylator pathway’ (Jass 2004). Similarly, the genetic 
Normal 
Epithelium 
Early 
Adenoma  
Intermediate 
Adenoma 
Late 
Adenoma 
Cancer 
Hypermutable Phenotype 
? role of promoter 
CpG methylation 
early in the 
pathway  - 
precursor lesions 
such as ACF
APC, p16 inactivation 
by methylation 
 
(Esteller et al 2000)
Aberrant  gene specific 
hypermethylation  
(www.mdanderson.org/methylation
CIMP 
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Low grade 
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High grade 
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Serrated Adenoma 
?
? TSG 
inactivation by 
methylation
ßcatenin/ 
APC (CIN)
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DCC, Smad2, 
Smad4 p53 
Aneuploidy
  p53 
UC assoc. Cancer - ? 
TSG inactivation by 
methylation OR 
TRF2 dysfunction 
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?
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mutations 
? TSG  inactivation 
by methylation 
?
Ageing, genomic 
hypomethylation,
?diet 
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alterations in the progression of flat adenomas (Paris type 0/11 clinical classification) to 
cancer remain elusive. In ulcerative colitis associated cancers unlike sporadic cancers, p53 
mutations appear to be an early event. It is not clear what triggers the progression from high 
grade dysplasia to cancer but it is possible that aberrant methylation of tumour suppressor 
genes or telomere dysfunction could initiate this – see proposed pathway in Figure 2. 
3. Telomere and telomere binding proteins 
Chromosome instability in colon epithelial cells and peripheral blood lymphocytes (PBLs) 
has been described in ulcerative colitis (Loeb et al 1999). Telomeres are specialized 
structures that cap and protect chromosome ends.  They are made up of a specific sequence 
of DNA repeats and form a T-loop structure which is stabilized by telomere associated 
proteins. Disruption of the T-loop structure causes the telomere to be recognised as a DNA 
double strand break, activates the DNA repair mechanism leading to telomere fusions and 
chromosome instability usually followed by apoptosis or senescence (Karlseder 2003). 
Telomere shortening occurs with each cell division and as a result of cellular stress.  This 
causes depletion of telomeric repeats and telomere binding proteins threatening the stability 
of the T-loop structure.  Telomere dysfunction also follows decreased expression of the 
telomere proteins which bind double stranded DNA. This causes disruption of the T-loop 
structure without significant telomere shortening and is known as telomere uncapping (Ben-
Porath et al 2004). Dysfunction can also occur with loss of the 3’ overhang, a single stranded 
stretch of DNA at the very end of the telomere protected by proteins known as telomere 
binding proteins such as TRF1, TRF2, TPP1, TIN2, RAP1 like POT-1 (15)(4,16). These 
proteins have been described to influence telomere maintenance (de Lange 2005) – Figure 3. 
 
 
Fig. 3. Telomere caps at the end of chromosomes. Magnified view showing ‘T’ loop structure 
of ‘Shelterin complex comprising the Telomere binding proteins 
3.1 Telomere dysfunction in UC 
The two main forms of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn’s 
disease (CD), are characterised by chronic intestinal inflammation and risk of progression to 
colon cancer (Ransohoff 1988). One proposed cause of the latter characteristic is chromosome 
instability, since the rearrangement of genetic material can lead to activation of oncogenes, loss 
of tumour suppressor genes and other changes that lead to uncontrolled cell growth.  
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Since genomic instability in peripheral blood mononuclear cells (PBMCs) has been used as a 
biomarker for global cancer risk in a number of diseases (Cottliar et al 2000), the latter 
observation suggests the possibility of a chromosome instability syndrome in UC that could 
affect all tissues.  One possible cause of chromosome instability aside from genomic DNA 
methylation is telomere dysfunction. In eukaryotic cells, telomeres are maintained by 
telomerase and the sub complex of telomere binding proteins. The chromosome instability 
observed in UC PBMC includes telomere fusions, suggesting the involvement of these 
structures in its generation.  Other observations linking telomeres and UC include 
decreased telomerase in the colitic colonic mucosa (Ussleman et al 2001), colitis-like 
ulcerations of the bowel in the telomerase knockout mouse (Lee et al 1998) and shortened 
telomeres in UC patients showing evidence of dysplasia (Arasaradnam et al 2009).  
Furthermore telomere shortening is not accelerated in peripheral blood mononuclear cells 
of UC patients compared with controls and therefore cannot be the mechanism by which 
chromosome instability arises in these cells (Getliffe et al 2005). Of particular note is the 
observation in rectal fibroblasts of UC patients showing slower telomere shortening 
particularly in those with late onset UC. This suggests those who develop UC later in life 
perhaps have more efficient anti-oxidant systems that protect against telomere damage. 
(Getliffe et al 2006) 
3.2 Role of telomere binding proteins (TBPs) in UC 
The telosome/shelterin complex consists of important regulatory telomere binding proteins 
to include TPP1 (tripeptidyl peptidase1 - formerly PTOP/PIP1/TINT1), POT1 (protection of 
telomere 1), TIN2 (TRF1 interacting nuclear factor 2), RAP1 (repressor activator protein), 
TRF1 (telomere repeat binding factor 1) and TRF2 (de Lange 2005).Telomere repeat binding 
factor 2 (TRF2) is a double stranded DNA binding protein which stabilizes the telomere T-
loop.  Cells lacking functional TRF2 have an extremely striking chromosome instability 
phenotype including frequent telomere fusions and erosion of the 3’ overhang, but no 
significant telomere shortening (de Lange 2002). Therefore decreased expression of TRF2 in 
UC peripheral mononuclear cells, might explain the chromosome instability observed in 
these cells.  More recent data also suggests that aside from maintaining telomeres, TRF2 may 
also be involved in the repair of DNA damage, including that which occurs at dysfunctional 
telomeres (Bradshaw et al 2005).  
3.2.1 Telomere Repeat Binding Factor 2 (TRF2) 
TRF2 mRNA expression is significantly decreased in activated T lymphocytes in both UC 
and CD, suggesting possible telomeric deficiency of this protein which could lead to 
destabilisation of the T-loop structure in these cells (da Silva et al  2010).  This telomere 
dysfunction could then cause activation of DNA damage response to repair what is 
perceived as a double strand break resulting in the telomere fusions previously observed in 
UC PBMCs. Thus decreased TRF2 mRNA levels in circulating T lymphocytes in IBD could 
be a putative bio-marker for potential active or refractory disease. It is uncertain if similar 
changes are present in the cells of the colonic mucosa in IBD where chromosomal 
abnormalities are thought to precede dysplasia and malignant change.  
The finding of low levels of TRF2 in IBD T lymphocytes makes it unlikely that this protein 
has a significant role in DNA repair mechanisms in this disease. An alternative explanation 
is that the cells have entered a phase of early senescence hence there is down regulation of 
telomere binding proteins (Risqué et al 2011). Telomere attrition has been demonstrated in 
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colonic epithelium of patients with ulcerative colitis which, could potentially initiate 
senescence (Risque et al 2008).  
Senescence is thought to act as a tumour suppressor forcing cells to undergo apoptosis 
rather than uncontrolled cellular proliferation which leads to cancer. mRNA expression 
levels of RAP1 for example is lower in activated T lymphocytes in UC (da silva et al 2010). 
RAP1 is closely regulated by TRF2 which in turn is stabilised by TIN2 to form a bridge 
across telomeric DNA. The reduced RAP1 expression in activated T lymphocytes hints at 
premature cellular senescence in circulating activated lymphocytes. It is yet unknown if 
these findings are replicated at mucosal level. Of interest is the observation of a positive 
association between RAP1 gene expression with 5 – aminosalicylate therapy (da silva et al 
2010). It is possible that 5 - aminosalicylate therapy may help stabilise the RAP1/ TRF2/ TIN2 
sub complex by increasing its expression thus providing better telomere dynamics in UC. This 
in turn may explain the clinical observation of the protective effect of 5 - aminosalicylate 
therapy in UC associated cancer providing further support for its chemo-prophylactic use 
(Rubin et al 2006). It is evident that the telomeric milieu at the chromosome end zone is 
intricately balanced with telomerase and telomere binding factors being the key players. The 
precise role and function of individual telomere binding proteins are largely unknown but it is 
clear that its coordinated interaction with telomere DNA is vital to maintaining telomere 
stability. Perturbance, as a result of local (mucosal) inflammation within this delicate sub 
complex of telomere proteins will, not surprisingly cause telomere dysfunction.  
4. Conclusion 
Further evaluation to measure N-33 expression (at mRNA and protein level) as well as to 
evaluate further epigenetic marking of tumour suppressor genes in larger UC cohorts 
including those with dysplasia and UC associated cancer are required. This will help 
elucidate further the role of DNA methylation in particular within the UC-CRC pathway. 
Additionally, studies to determine associations with habitual dietary intake are required – 
the latter being an important variable given the modifiable effect of diet on DNA 
methylation. Finally the role of TBPs in particular mucosal TRF2 in UC patients in the 
clinical setting of progressive dysplasia and colon cancer will be vital to elucidate its role as 
a putative biomarker of cancer risk. 
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